Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Immunization in tumor prevention.

Guido Forni1, Claudia Curcio, Michela Spadaro

  • 1Department of Clinical and Biological Sciences, University of Turin, I-10043 Orbassano, Italy. guido.forni@unito.it

International Immunopharmacology
|July 16, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting the cancer metabolism-immunity interface: update and perspectives.

Experimental hematology & oncology·2026
Same author

Talazoparib engages innate immune activation via PARP trapping-dependent cGAS/STING activation in Ewing Sarcoma.

Cancer letters·2026
Same author

Prostatic fibroblast reprogramming by Interleukin-30 activates prostate cancer metastasis programs.

Molecular biomedicine·2026
Same author

Exploring the role of Teneurin-4 in solid tumours: current evidence and potential therapeutic implications.

Cancer letters·2026
Same author

HER-2 therapeutic vaccine is not hampered by concurrent HER-2 monoclonal antibody.

NPJ vaccines·2026
Same author

Early Cancer Detection: What's Going on and What's Next.

MedComm·2026

Activating immunity can prevent tumors, especially when targeting oncogenic growth factor receptors like Her-2/neu. This approach was successfully demonstrated in preventing mammary carcinomas in mice.

Area of Science:

  • Oncology
  • Immunology
  • Cancer Prevention

Background:

  • Emerging data suggest the immune system can be harnessed for tumor prevention.
  • The immune environment in early-stage cancer is often intact and not tolerant to tumor antigens.
  • Oncogenic growth factor receptors represent viable targets for cancer immunoprevention.

Purpose of the Study:

  • To explore the potential of immune system activation for tumor prevention.
  • To investigate oncogenic growth factor receptors as targets for immunoprevention.
  • To summarize evidence supporting the immunoprevention of mammary carcinomas using Her-2/neu transgenic mouse models.

Main Methods:

  • Review of experimental data on cancer immunity and prevention.
  • Analysis of oncogenic growth factor receptors as tumor antigens.

Related Experiment Videos

  • Case study of Her-2/neu transgenic mice for mammary carcinoma prevention.

    • Main Results:

    • Experimental data support the activation of immunity for tumor prevention.
    • Her-2/neu transgenic mice demonstrated successful prevention of mammary carcinomas.
    • The Her-2/neu gene product serves as an effective antigen for preventive treatments.

    Conclusions:

    • Immune system activation is a promising strategy for cancer prevention.
    • Targeting oncogenic growth factor receptors, such as Her-2/neu, is a valid approach for immunoprevention.
    • Further research into Her-2/neu antigen properties and immune responses is warranted.